1.Abba K, Kirkham AJ, Olliaro PL, Deeks JJ, Donegan S et al., (2014). Rapid tests for diagnosing malaria caused by Plasmodium vivax or other less common parasites. Infectious Diseases Group

2.André M Siqueira, Lucas I Coutinho, Rafael L Gurgel, Willian CS Su (2014). Slow clearance of Plasmodium vivax with chloroquin amongst children younger than six months of age in the Brazilian Amazon. Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 109 (5): 540-545.

3.Anam A Waheed, Najia K Ghanchi, KarimARehma (2015). Vivax malaria and chloroquine resistance: A neglected disease as an emerging threat. Malaria Journal, 2015 14:146

4.Anil Pareek,Nitin Chandurkar, Nithya Gogtay (2015). Sustained Release Formulation of primaquin for prevention of relapse of Plasmodium vivax malaria: A randomized, double-blind, comparative,multicentric Study. Malaria Research and Treatment, Vol. 2015, Article ID 579864, 8.

5.Atul Goel, Ankit Mangla and Tejinder Singh et al., (2014). Changing pattern of vivax malaria. Pediat Therapeut 4: e124. doi: 10.4172/2161-0665.1000e1

Hình 1

6.Baird JK, Caneta-Miguel E et al., (2003). Survey of resistance to chloroquin of falciparum and vivax malaria in Palawan, the Philippines. Ann Pharmacother, 2003; 37(4):526-9.

7.Baird JK, Hoffman LS et al., (2004). Primaquin therapy for malaria. Clinical and Infectious diseases 39:1336-1345.

8.Baird, J. Kevin et al., (2007). Neglect ofPlasmodium vivax malaria. U.S. Navy Research, pp. 96

9.Baird JK et al., (2009). Resistance to therapies for infection by Plasmodium vivax., Clin Microbiol Rev, 2009;22(3):508-34.

10.Baird J. Kevin, Neena Valecha, Stephan Duparc et al., (2016). Diagnosis and treatment of vivax malaria diagnosis and treatment of Plasmodium vivax malaria. The American Society of Tropical Medicine and Hygiene, published o­nline October 5, 2016; doi:10.4269/ajtmh.16-0171.

11.Baird J. Kevin et al., (2016). Attacking Plasmodium vivax. The American Society of Tropical Medicine and Hygiene, ublished o­nline October 5, 2016; doi:10.4269/ajtmh.16-0517

12.BS Bal, Ashok Duggal, Sachin Khurana, Jasleen Kaur (2012). Haematological abnormalities in Plasmodium vivax malaria. JIACM 2012; 13(3):236-8

13.Barnardas C, Ratsimbasoa A, Tichit M et al., (2008). Plasmodium vivax resistance to chloroquin in Madagasca: Clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes. Antimicrob Agents Chemother; 52(12):4233-40.

14.Bassat Q, Mulenga M, Tinto H, Piola P et al., (2009). Dihydroartemisinin-piperaquin and artemether-lumefantrin for treating uncomplicated malaria in African children: A randomised, non-inferiority trial. PLoS o­ne 4(11): e7871.

Hình 2

15.Bruno B A, Antonio R F, Sebastiao et al., (2010). Severe Plasmodium vivax malaria exhibits marked inflamatory imbalance. Malaria Journal 2010, 9:13.

16.Yan Bi, Weiwei Yu, Wenbiao Hu, Hualiang Lin (2013). Impact of climate variability o­n Plasmodium vivax and Plasmodium falciparum malaria in Yunnan province, China. Parasites & Vectors 2013, 6:357

17.CDC (2015). Manual for quantification of malaria commodities. Rapid diagnostic tests and artemisinin-based combination therapy for first line treatment of Plasmodium falciparum malaria.

18.Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q et al., (2007). Relapse of Plasmodium vivax infection result from clonal hypnozoites activated at predeterminated intervals. Journal of infectious diseases, 195:934-941.

19.Chotivanich K, Udomsangpetch R, McGready R, Proux S et al., (2002). Central role of the spleen in malaria parasite clearance. J. Infect Dis;185(10):1538-41.

20.Clarissa M. Moreira, Mahmoud Abo‑Shehada, Ric N. Price (2015). A systematic review of sub‑microscopic Plasmodium vivax infection. Malar J (2015) 14:360.

21.David G. Lalloo, Delane Shingadia, David J. Bell et al., (2016). UK malaria treatment guidelines 2016. Journal of Infection 2016;72; 635-649.

22.Dhanpat K. Kochar, Vishal Saxena, Narvachan Singh et al., (2005). Plasmodium vivax malaria. Emerging Infectious Diseases, vol.11, No.1.

23.Djimde A, Doumbo OK, Cortese JF, et al. (2001). A molecular marker for chloroquine-resistant falciparum malaria. N. Engl J Med; 344:257-263.

24.Nicholas M Douglas, Nicholas M Anstey, Pierre A Buffet (2012). The anaemia of Plasmodium vivax malaria. Malaria Journal, 2012, :135

25.ECDC (2012). Rapid risk assessment autochthonous Plasmodium vivax malaria in Greece. European Centre for Disease Prevention andControl, Stockholm.

26.Fabio T.M. Costa, Stefanie C.P. Lopes, Letusa Albrecht (2012). On the pathogenesis of Plasmodium vivax malaria: Perspectives from the Brazilian field. J. Parasitol. (2012), doi.org/10.1016/j.ijpara.2012.08.007

27.Fernando Fonseca Val, Vanderson Souza Sampaio, Maria Belén Cassera et al., (2014). Plasmodium vivax malaria elimination: should innovative ideas from the past be revisited? Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol.109(5): 522-524.

Hình 3

28.FontouraPS, Finco BF, Lima NF, de Carvalho JF, Jr., Vinetz JM et al., (2016). Reactive case detection for Plasmodium vivax malaria elimination in rural Amazonia. PloS Negl Trop Dis 10(12): e0005221. doi:10.1371

29.Fryauff DJ, Tuti S, Mardi A et al., (2004). Chloroquine resistant Plasmodium vivax in transmigration settlement of west Kalimantan, Indonesia. Am J Trop Med Hyg; 59 (4):513-8.

30.Gething PW, Elyazar IRF, Moyes CL, Smith DL, Battle KE et al., (2012). A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PloS Negl Trop Dis 6(9):e1814.

31.Giao PT, Binh TQ, Peter VJ, Hung LQ, Nam NV et al., (2002). Artemisinins or chloroquine for blood stage Plasmodium vivax malaria in Vietnam. Tropical Medicine and International health, 2002, 7:856-864

32.Gogtay NJ, Desai S, Kadam VS et al., (2000). Relapse pattern of Plasmodium vivax in Mumbai: A study of 283 cases of vivax malaria. J. Assoc Physicician India;48(11):1085-6.

33.Goller JL, Jolley D, Ringwald P, Biggs BA (2007). Regional differences in the response of Plasmodium vivax malaria to primaquin as anti-relapse therapy. American Journal of Tropical medicine and Hygiene, 76:203-207.

34.Ghulam Rahim Awab, Sasithon Pukrittayakamee et al., (2010). Dihydroartemisinin - piperaquine versus chloroquine to treat vivax malaria in Afghanistan: An open randomized, non-inferiority, trial. Malaria Journal 9:105.

35.Guthmann JP, Pittet A, Lesage A, Imwong M, Nosten F et al., (2008). Plasmodium vivax resistance to chloroquin in Dawei, Southern Myanmar. Trop Med Int Health. 2008;13(1):91-8.  

36.Hai-Mo Shen, Shen-Bo Chen, Yue Wang, Jun-Hu Chen (2015). Whole genome sequencing of a Plasmodium vivax isolate from the China-Myanmar border area. Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 110(6): 814-816.

37.Hampâté Ba, Craig W. Duffy, Ambroise D. Ahouidi (2016). Widespread distribution of Plasmodium vivax malaria in Mauritania o­n the interfaceof the Maghreb and West Africa. Malaria Journal 2016;15:80

38.Imwong M, Snounou G, Nurhayati et al. (2007). Plasmodium vivax infection usually result from activation of heterologous hypnozoites. Journal of Infectious Diseases, 195:927-933.

Hình 4

39.Jan Peter Verhave et al., (2013). Experimental, therapeutic and natural transmission of Plasmodium vivax tertian malaria: scientific and anecdotal data o­n the history of Dutch malaria studies. Parasites & Vectors 2013, 6:19

40.Jean Francois Faucher, Anne Pauling Bellanger, Catherine Chirouze et al., (2015). Primaquine for radical cure of Plasmodium vivax and Plasmodium ovale malaria: An observational survey (2008-2010). International Society of Travel Medicine 2013; Volume 20 (Issue 2): 134-136

41.Jean Popovici, Didier Ménard et al., (2015). Challenges in antimalarial drug treatment for vivax malaria control. Trends in Molecular Medicine, 2015, Vol. 21, No.12: 1-13

42.Jetsumon Sattabongkot, Takafumi Tsuboi, Gabriela E. Zollner et al., (2004). Plasmodium vivax transmission: Chances for control? TRENDS in Parasitology, vol.20 No.4 April 2004

43.John Barnwell, Jane Carlton, William Collins (2007). Neglected burden of human vivax malaria: Comparative analysis of Plasmodium vivax and key related species. Plasmodium comparative genomics writing group

44.Katherine E Battle, Markku S Karhunen, Samir Bhatt et al., (2014). Geographical variation in Plasmodium vivax relapse. Malaria Journal 2014, 13:144.

45.Katherine E. Battle, Peter W. Gething, Iqbal R.F. Elyazar (2012). The Global Public Health Significance of Plasmodium vivax. Advances in Parasitology, Vol.80, ISSN 0065-308X, dx.doi.org/10.1016/B978-0-12-397900-1.00001-3

Hình 5

46.Katherine E. Battle, Carlos A. Guerra, Nick Golding et al., (2015). Global database of matched Plasmodium falciparum and P. vivax incidence and prevalence records from 1985-2013. www.nature.com/data/ 2:150012, doi: 10.1038/sdata.2015.12

47.Kanchana Rungsihirunrat, Poonuch Muhamad, Wanna Chaijaroenkul et al., (2015). Plasmodium vivax drug resistance genes; Pvmdr1 and Pvcrt-o Polymorphisms in relation to chloroquin sensitivity from a malaria endemic area of Thailand. Korean J Parasitol Vol. 53, No.1: 43-49.

48.Ketema Tsige, Ketema Bacha, Tarekegn Birhanu et al., (2009). Chloroquin-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, south-west Ethiopia. Malaria journal; 8:177.

49.Khojasteh Sharifi-Sarasiabi, Ali Haghighi, Bahram Kazemi et al., (2016). Molecular surveillance of Plasmodium vivax and Plasmodium falciparum dhfr mutations in isolates from southern Iran. Rev. Inst. Med. Trop. Sao Paulo, 2016;58:16

50.Kitchener S, Nasveld P, Edstein MD et al., (2007). Tafenoquine for the treatment of recurrent Plasmodium vivax malaria. Am J Trop Med Hyg, 2007:76 (3):494-6

51.Kurcer MA, Simek Z, Kurcer Z et al., (2006). The decreasing efficacy of chloroquin in the treatment of Plasmodium vivax malaria, in Sanliurfa, south-eastern Turkey. Ann Trop Med Parasitol, 2006;100(2):109-13.

52.K Stepniewska, Ashley E, Lee SJ, Anstey N, Barnes KI, Binh TQ, D'Alessandro U (2010). In vivo parasitilogical measures of artemisinine susceptibility. J Infect Dis. 15;201(4):570-9.

53.Laurent Brutus, José Santalla, Dominique Schneider (2013). Plasmodium vivax malaria during pregnancy, Bolivia. Emerging Infectious Diseases, vol. 19, No. 10, October 2013

Hình 6

54.Lee KS, Kim TH, Kim ES et al., (2009). Short report: chloroquin resistant Plamodium vivax malaria in the Republic of Korea. Am J Trop Hyg, 80(2):215-7.

55.Leeha Singh, Surbhi Rathi, Santosh Kondekar et al., (2016). Per protocol analysis of therapeutic efficacy of chloroquine for the treatment of Plasmodium vivax malaria in children. International journal contemporary paediatrics. http://dx.doi.org/10.18203/2349-3291.ijcp20161909

56.Lígia Antunes Gonçalves, Pedro Cravo, Marcelo Urbano Ferreira (2014). Emerging Plasmodium vivax resistance to chloroquine in South America: an overview. Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol.109 (5): 534-539.

57.Lili Yuan, Ying Wang, Daniel M. Parker, Bhavna Gupta et al., (2015). Therapeutic responses of Plasmodium vivax malaria to chloroquinand primaquine treatment in Northeastern Myanmar. Antimicrob Agents Chemother 59:1230-1235.

58.Lemu Golassa, Berhanu Erko, Frederick N Baliraine, Abraham Aseffa (2015). Polymorphisms in chloroquin resistance-associated genes in Plasmodium vivax in Ethiopia. Malaria Journal (2015) 14:164.

59.Luciano Rodrigues Simões, Eduardo Rodrigues Alves-Jr, Daniele Ribatski-Silva (2010). Factors associated with recurrent Plasmodium vivax malaria in Porto Velho, Rondônia State, Brazil, 2009. Cad. Saúde Pública, Rio de Janeiro, 30(7):1403-1417, jul, 2014

60.Márcia A. Alexandre, Cynthia O. Ferreira, André M. Siqueira. Severe Plasmodium vivax malaria, Brazilian Amazon. Emerging Infectious Diseases, vol.16, No.10:1611-1614

61.Mohamed H. Abdelraheem, Musab M. A. Albsheer, Hiba S. Mohamed (2016). Transmission of Plasmodium vivax in Duffy-negative individuals in central Sudan. Trans R Soc Trop Med Hyg; 110:258-260, doi:10.1093/trstmh/trw014

62.Mohapatra MK, Padhiary KN, Mishra DP et al., (2002). Atypical manifestations of Plasmodium vivax malaria. Indian J Malariol;39(1-2):18-25.

63.Mueller I, Galinski MR, Baird JK, Carlton JM et al. (2009). Key gaps in the knowledge of Plasmodium vivax, a neglected human parasite. Lancet Infect Dis 2009; 9(9): 555-66.

64.Nacher M, Silachamroon U, Singhavisanon P (2004). Risk factors for Plasmodium vivax gametocyte carriage in Thailand. Am J Trop Med, 2004;71(6):693-5.

65.Nandy A, Addy M, Maji AK et al., (2003). Monitoring the chloroquine sensitivity of Plasmodium vivax from Calcutta and Orissa, India. Ann Trop Parasitol; 97 (3):215-20

Hình 7

66.Nasveld P, Kitchner S et al., (2005). Treatment of acute vivax malaria with tafenoquine”. Trans R Soc Trop Med Hyg, 2005; 99(1):2-5

67.Orjuela-Sanchez P, Da Silva NS, da Silva-Nune M et al.,(2009). Recurrent parasitemia and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia. Am J Trop Med and Hyg; 81(6):961-8.

68.Park JW, Jun G, Yeom JS et al., (2009).Plasmodium vivax malaria: Status in the republic of Korea following reemergence. Korean J Parasitol;47 Suppl:S39-50.

69.Price RN, Tjitra E, Guerra CA et al., (2007). Vivax malaria: Negleted and not benign. Am J Trop Med Hyg; 77(6 suppl):79 - 87.

70.Price RN, Douglas NM, Anstey NM et al., (2009). New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquin resistance. Curr Opin Infect Dis; 22(5); 430-5.

71.Purva Gupta, Rajni Sharma, Jagdish Chandra, Vineeta Singh (2016). Severe malaria due to Plasmodium vivax: Case report. Curr pediatr res 2016; 20 (1&2): 24-28.

72.Ric N Price, Lorenz von Seidlein, Neena Valecha, Francois Nosten, J Kevin Baird et al., (2014). Global extent of chloroquine-resistant Plasmodium vivax: A systematic review and meta-analysis. Lancet Infect Dis2014;14:982-91.

Hình 8

73.Rosalind E. Howes, Katherine E. Battle, Kamini N. Mendis et al., (2013). Global epidemiology of Plasmodium vivax. Published o­nline July 11, 2016; doi:10.4269/ajtmh.16-0141.

74.Rosalind E., Howes Katherine E., Battle Nick Golding, Simon I. Hay (2015). Plasmodium vivax thematic review epidemiology. Malaria Atlas project, Oxford university

75.Roy M, Bouma MJ, Ionides EL, Dhiman RC, Pascual M (2016). The Potential elimination ofPlasmodium vivax malaria by relapse treatment: Insights from atransmission model and surveillance data from NW India. PLoS Negl Trop Dis 7(1): e1979.

76.Rowena E. Martin et al., (2004). The malaria parasite's chloroquine resistance transporter is a member of the drug/ metabolite transporter superfamily. Molecular Biology and Evolution 2004 21(10):1938-49.

77.Rupam Tripura, Thomas J. Peto, Jeremy Chalk, Sue J. Lee (2016). Persistent Plasmodium falciparum and Plasmodium vivax infections in a western Cambodian population: implications for prevention, treatment and elimination strategies. Malar J (2016) 15:181.

78.Ruth O. Payne, Paul M. Griffin, James S. McCarthy, Simon J. Draper (2017). Plasmodium vivax controlled human malaria infection: Progress and Prospects. Trends in Parasitology, February 2017, Vol.33, No. 2.

Hình 9

79.Sharrock WW, Suwannarusk R, Lek-Uthai U et al., (2008). Plasmodium vivax trophozoites insensitive to chloroquin. Malarial journal 27;7:94.

80.Soto J, Toledo J, Gutierrez P et al., (2001). Plasmodium vivax clinically resistant to chloroquin in Colombia. Am J Trop Hyg Aug; 65(2):90-3.

81.Stano I, Suprijanto S, Nurhayati et al., (2009). Resistance to chloroquin by Plasmodium vivax at Alor in the Lessser Sundas archipelago in eastern Indonesia. Am J Trop Med Hyg, 2009 Aug;81(2):338-42.

82.Hiwot Teka, Beyene Petros, Lawrence Yamuah et al., (2008). Chloroquin-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malaria journal, 2008 Oct 29; 7-220.

83.Pham Vinh Thanh, Hong Nguyen Van, Nguyen Van Van, Melva Louisa,Kevin Baird et al., (2015). Confirmed Plasmodium vivax resistance to chloroquin in Central Vietnam. Antimicrob. Agents Chemother. doi:10.1128/AAC.00791-15

84.Tjitra E, Anstey NM, Sugiarto P et al. (2008). Multidrug-resistant Plasmodium vivax associated with severe and fetal malaria: A prospective study in Papua, Indonesia. Pls Med, 2008 Jun 17; 5(6):128.

85.Toi Van Pham, Phuong Pham Nguyen, Tho Nguyen Duc Khanh, Nhien Nguyen Thanh Thuy, Ca Nguyen Thuy Nha, Thomas Pouplin, Jeremy Farrar, Guy E. Thwaitesa and Hien Tran Tinh (2016). An HPLC method with diode array detector for the simultaneous quantification of chloroquin and desethylchloroquine in plasma and whole blood samples from Plasmodium vivax patients in Vietnam, using quinine as an internal standard. Biomed. Chromatogr. 2016; 30: 1104–1111

Hình 10

86.Vijaykadga S, Rojanawatsivej C, Congpoung K et al., (2004). Assessment of therapeutic efficacy for vivax in Thailand. Southeast Asian J Trop Med public Health, 2004; 35(3):566-9.

87.Vinetz JM et al., (2006). Emerging chloroquin-resistant Plasmodium vivax (benign tertian) malaria: the need for alternative drug treatment. Clin Infect Dis 2006 Apr 15;42(8):1073-4.

88.Nicholas J White (2010). Determinants of relapse periodicity in Plasmodium vivax malaria. Malaria Journal 2011, 10:297.

89.USAID (2016). Manual for quantificationof malaria commodities rapid diagnostic tests and artemisinin-based combination therapy for first-line treatment of Plasmodium falciparum..

90.Vinod P. Sharma, Vas Dev, Sobhan Phookan (2015). Neglected Plasmodium vivax malaria in northeastern States of India. Indian J med Res 141:546-555

91.White N. et al., (2011). Determinants of relapse periodicity inPlasmodium vivax malaria. Malaria Journal 2011, 10:297

92.Michael T.White, GeorgeShirreff, StephanKarl (2017). Variation in relapse frequency and the transmission potential of Plasmodium vivax malaria. Proc. R. Soc. B 283:20160048.

93.Nicholas J. White, Tran T. Duong, Chirapong Uthaisin (2016). Antimalarial activity of KAF156 in falciparum and vivax malaria. N Engl J Med 2016;375:1152-60.

Hình 11

94.WHO (2008). Methods and techniques for clinical trials o­n antimalarial drug efficacy: genotyping to identify parasite populations.

95.WHO (2009). Methods for surveillance of antimalarial drug efficacy.

96.WHO (2009). Parasitological confirmation of malaria diagnosis.

97.WHO (2010). Global report antimalarial drugs efficacy & drugs resistance

98.WHO (2011). Methods and technique for assessing exposure to antimalarial drugs in clinical field studies. Informal consultation organized by the WHO with the technical supports of the world wide antimalarial resistance network.

99.WHO (2012). ICH - GCP Guidelines for Clinical Trials

100.WHO (2012). WHO urges action as drug-resistant malaria spreads.

101.WHO (2012). Update WHO policy recommendation, Single dose primaquine as a gametocytocide in Plasmodium falciparum malaria

102.WHO (2013). Emergency response to artemisinin resistance in the greater Mekong subregion, Regional framework for action 2013-2015

103.WHO (2013). Case management: Guide for tutors, Traning module for malaria control.

104.WHO (2013). Updated WHO Policy Recommendation: Single dose primaquin as a gametocytocide in Plasmodium falciparum malaria

Hình 12

105.WHO (2013), Management of severe malaria: A practical hanbook

106.WHO (2013) Malaria Policy Advisory Committee to the WHO: Conclusions and recommendations of March 2013 meeting, Malaria Policy Advisory Committee and Secretariat, Malaria Journal 2013, 12:213

107.WHO (2015). Guidelines for the treatment of malaria, third edition.

108.WHO (2015). A WHO external quality assurance scheme for malaria nucleic acid amplification testing, Global Malaria Programme - Meeting report.

109.WHO (2015). Control and Elimination of Plasmodium vivax malaria. A technical brief

110.WHO (2015). Confronting of Plasmodium vivax malaria.

111.WHO (2016). World malaria report 2015.

Hình 13

112.WHO (2016). Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale malaria, Policy brief

113.WHO (2016). World malaria report 2016.

114.WHO (2016). WHO’s emergency response to artemisinin resistance, sept.2016

115.WHO (2016). Methods manual for laboratory quality control. Testing of malaria rapid diagnostic tests.

116.S. K. Wijesekera, R. Carter, Rathnayaka et al., (1996). A malaria parasite toxin associated with Plasmodium vivax paroxysms. Clin Exp Immunol 1996;104:221-227

117.Yehenew A Ebstie1, Solomon M Abay, Wondmagegn T Tadesse (2016). Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Design, Development and Therapy, Open Access, dx.doi.org/10.2147/DDDT.S61443

118.Yeom JS, Jun G, Kim JY, Lee WJ, Shin EH et al., (2012). Status of Plasmodium vivax malaria in the republic of Korea, 2008-2009: decrease followed by resurgence. Trans R Soc Trop Med Hyg.;106(7):429-36.

119.Yonne F Chehuan, Monica RF Costa, Jacqueline S Costa (2013). In vitro chloroquine resistance for Plasmodium vivax isolates from the Western Brazilian Amazon. Malaria Journal 2013, 12:226.

Các nội dung khác »

---